Bone marrow 'boosts' following T cell-depleted haploidentical bone marrow transplantation

Area of Science:

• Immunology
• Hematology
• Transplantation Medicine

Background:

• Patients undergoing T cell-depleted bone marrow transplantation (BMT) for non-malignant conditions may experience delayed T cell immunity recovery.
• This immune deficiency can persist despite evidence of engraftment, necessitating further intervention.

Purpose of the Study:

• To evaluate the efficacy of a second, T cell-depleted bone marrow transplant (BMT boost) from the same haploidentical donor in patients with delayed T cell immunity recovery.
• To assess the impact of BMT boosts on T cell function, immune cell populations, and patient survival.

Main Methods:

• Nine patients with severe combined immunodeficiency or aplastic anemia received a second T cell-depleted BMT from a haploidentical donor without conditioning (except one patient receiving ATG).
• No graft-versus-host disease (GVHD) prophylaxis was administered during either the initial or boost transplant.
• Immune function, including lymphocyte proliferative responses and T cell subset percentages (CD3+, CD4+), was monitored post-boost.

Main Results:

• Eight of nine patients survived at a median follow-up of 2.9 years.
• Following BMT boost, T cell function significantly improved, with lymphocyte proliferative responses increasing at least eight-fold.
• The mean percentage of CD3+ and CD4+ lymphocytes increased significantly post-boost, indicating enhanced T cell reconstitution.

Conclusions:

• Bone marrow boosts are an effective immunotherapy for improving T cell immunity in patients with inadequate immune recovery after T cell-depleted BMT.
• This strategy shows promise for enhancing outcomes in allogeneic BMT, potentially including those for malignancy treatment.